What’s New in Thermoplastic Polyurethanes How ChronoFlex™ S Delivers Softness and Strength for Implantable Medical Devices

Why It Matters

The new TPU reduces manufacturing complexity and cost while enabling softer, more patient‑friendly implantable devices, opening design space previously limited to silicone.

Key Takeaways

• 60A TPU matches silicone softness while surpassing strength.
• 36% USDA‑certified biobased content supports sustainability goals.
• Eliminates adhesives, reducing production time and cost.
• Processes via extrusion, injection molding, dip‑casting, and more.
• Softens at body temperature to roughly 54A hardness.

Pulse Analysis

The medical device sector has long wrestled with a trade‑off between softness and durability. Silicone offers excellent compliance but lacks the mechanical robustness required for high‑stress applications such as cardiovascular catheters. Conversely, traditional TPUs provide strength but have been limited to hardness levels of 70A or higher, leaving a materials gap for ultra‑soft implants. ChronoFlex S bridges this divide by delivering a 60A hardness—soft enough for minimally invasive procedures—while maintaining tensile strengths that exceed silicone, thereby expanding the engineering toolkit for designers.

Beyond its mechanical profile, ChronoFlex S brings processing versatility that can streamline production lines. The polymer can be melted, extruded, injection‑molded, or dip‑cast using existing equipment, and it bonds directly to polyamide elastomers without adhesives or tie‑layers. This eliminates extra pretreatment steps, cuts labor costs, and reduces the risk of delamination. Its 36% biobased content aligns with manufacturers’ sustainability targets, and the absence of plasticizers mitigates long‑term leaching concerns, enhancing regulatory confidence for both short‑ and long‑term implants.

From a business perspective, the material’s ability to soften further at body temperature—dropping to roughly 54A—offers clinicians a device that conforms more naturally to vascular anatomy, potentially improving patient outcomes and reducing procedural complications. The combination of lower manufacturing overhead, expanded design flexibility, and eco‑friendly credentials positions ChronoFlex S as a strategic differentiator for companies seeking to launch next‑generation neuro‑vascular, cardiac, and orthopedic implants. Early adopters could capture market share by offering devices that are both gentler on patients and more cost‑effective to produce, accelerating innovation across the implantable device landscape.